Nonribosomal peptides are processed on multifunctional enzymes called nonribosomal peptide synthetases (NRPSs), whose modular multidomain arrangement allowed the rational design of new peptide products. However, the lack of natural competence and efficient transformation methods for most of nonribosomal peptide producer strains prevented the in vivo manipulation of these biosynthetic gene clusters. In this study, we present methods for the construction of a genetically engineered Bacillus subtilis surrogate host for the integration and heterologous expression of foreign NRPS genes. In the B. subtilis surrogate host, we 
Introduction
Nonribosomal peptides represent a large family of bioactive secondary metabolites produced by bacteria and fungi. Numerous of these peptides are pharmacological important drugs like the immunosuppressive cyclosporin A or the antibiotics penicillin, vancomycin, and bacitracin. Other nonribosomally synthesized peptides like siderophores are associated with pathogenicity of microorganisms. The extraordinary variety of biological properties is a result of the enormous structural diversity in this group of natural products.
A vast set of substrates like amino acids, hydroxyl as well as carboxylic compounds are known to be incorporated into the peptide chain. In addition, the assembled residues can be further modified by epimerization, N -methylation, acylation, glycosylation or heterocyclization. The final products display linear, cyclic and/or branched peptide backbones (1, 2) .
Nonribosomal peptide assembly is catalyzed by large multifunctional nonribosomal peptide synthetases (NRPSs) 1 . Sequencing of several genes encoding NRPSs combined with recent biochemical and structural studies revealed a universal modular scaffold for t hese enzymes.
Each module represents a functional unit including a full complement of active sites for recognition, activation and incorporation of one constituent into the product. According to the multiple thiotemplate mechanism (3), in the first step the adenylation (A) domain recognizes and activates the cognate substrate by ATP hydrolysis to the corresponding adenylate.
(4'PPan) cofactor, which is attached to an invariant serine residue of the peptidyl carrier protein domain (PCP) , that is located downstream of the A -domain. Posttranslational modification of the PCP-domain is catalyzed by a 4'PPan-transferase (PPTase) (4) . Normally, genes encoding PPTases are associated with most of NRPS biosynthetic gene clusters. During the elongation reaction the PCP-tethered precursors are coupled to the nascent peptide chain by the condensation (C) domain, which is located between each consecutive pair of activating units. In addition to the A -, PCP-and C-domains, modifying domains are found in modules that incorporate modified residues. Final release of the full-length peptide chain by cyclization or hydrolysis is catalyzed by a thioesterase l ike (Te) domain residing at the C-terminus of the last NRPS. As a consequence of this assembly-line mechanisms, the primary sequence and the extent of modification of the final NRPSs product is controlled by a linear sequence of catalytic domains and modules (2, 5, 6) .
Based on the modular arrangement of NRPSs, engineered manipulation of the nonribosomal protein templates enabled the rational design of new peptide products. Some of the strategies that have been devised were shown to yield f unctional hybrid templates in vitro (7, 8) . The directed replacement of minimal modules (A-PCP-domains) (9, 10) as well as whole modules (11) in the surfactin biosynthesis operon (srfA) of Bacillus subtilis in vivo led to a predicted alteration of the amino acid sequence in the peptide product. Furthermore, truncated lipopeptide-derivatives could be produced in vivo by moving the carboxyl-terminal intrinsic
Te-domain (12) downstream of the internal PCP-domains of the srfA-biosynthesis operon.
The cyclic branched peptide antibiotic bacitracin is produced by Bacillus licheniformis ATCC 10716, a strain that lacks natural competence. Genetic manipulations of the bacitracin biosynthesis operon h ave therefore so far been difficult to realize. However, the structural properties of the branched cyclic, thiazoline-ring containing peptide make bacitracin a desirable task to employ the genetic engineering strategies devised for NRPSs (13) .
Therefore, we constructed a heterologous expression system for the entire 49 kb comprising 
Experimental procedures
Bacterial strains and culture media -Bacterial strains used in this investigation are listed in Table 1 . Cells were grown in 2xYT medium (38) , in Difco Sporulation m edium (DSM) (39) or in modified SpII medium (40) . For Bacillus, cultures supplemented with 25 µg/ml erythromycin, 1 µg/ml lincomycin, 5 µg/ml chloramphenicol, 10 µg/ml tetracycline, and 10 µg/ml kanamycin were used. In E. coli final concentrations of 25 µg/ml kanamycin and 100 µg/ml ampicillin were used. Fig.3 ). Thereby, the 5' homologous regions of bacA was extended from 1 kb (KE300) to Surfactin preparation and detection -The lipopeptide surfactin (see Fig.1 ) was extracted as described previously (10) . The hemolytic acitivity of surfactin was analyzed using blood-agar plates (39). For the construction of the srfA-deletion plasmid pKE19, the upstream h omologous region of srfA (2.5 kb) containing srfA-operator, promoter and RBS was cloned (see Fig.2 ). To obtain a B. subtilis srfA-deletion strain that still maintains its genetic competence, the transcriptional control of comS (138 bp) was restored by fusion to the RBS of the srfApromotor. Its start codon was altered from TTG to ATG to facilitate an efficient initiation of translation. The downstream homologous region of srfA (939 bp) (see Fig.2 ) was determined in a way that the transcriptional regulation of the succeeding open reading frame ycxA (1.2 kb) was restored.
kb (KE310
For transformation we used the B. subtilis derivative TS30 (9), containing a cat-resistance marker in the srfA-C site, that permits screening on double crossover integration (see Fig.2 ).
After transformation of B. subtilis TS30 with the srfA-deletion plasmid pKE19 three transformants with the phenotype MLS R and Cm S were selected. The correct integration was confirmed by southern blotting analysis that revealed the correct substitution by double crossover (data not shown). The resulting strain carrying the deletion of the entire srfA-operon (26.1 kb) including the surfactin synthetases A -C and srfA-TE was designated KE10 (see strain, which was shown to produce the 598 kDa BacA protein in significant amounts during the transition state growth phase, was designated KE320 (see Fig.4A ). In this recombinant strain KE320, an improvement of BacA production, whose gene is regulated by the σ Adependent bac-promotor in B. subtilis was observed.
Partial purification and in vitro analysis of BacA from B. subtilis KE320 -BacA (598 kDa) was partially purified using (NH 4 ) 2 SO 4 precipitation and size exclusion chromatography (see Fig.4B ). The activity of the protein could be demonstrated by activation of substrate amino acids and thioester formation assay.
The predicted specificity of BacA towards L-isoleucine, L-cysteine and L-leucine was confirmed, however, no specificity towards L-glutamate was observed (see Fig.4C ).
Investigations concerning the specificity of the wild type protein BacA purified from B.
licheniformis ATCC 10716 revealed also no activation of L-glutamate, too (23).
Thioester formation of the substrate amino acids L-isoleucine and L-leucine was also demonstrated (see Fig.4D 6 ). Correct integration of the intact bacRS was confirmed by southern hybridization (data not shown). The obtained strain harboring the entire bacitracin biosynthesis gene cluster residing in the former srfA-locus was designated B. subtilis KE360 (see Fig.6 ). In this strain, the three nonribosomal peptide synthetases BacABC were detected by SDS-PAGE (see Fig.7 ). The production of the bacitracin sensing proteins BacRS and the ABC-transporter BcrABC was confirmed by western blot analysis (data not shown).
Heterologous bacitracin production in B. subtilis KE360 -B. subtilis strain KE360 was
shown to produce a mixture of cyclic bacitracins with the bioactive bacitracin A and its oxidation product bacitracin F as the main components (26) (see Fig.8 ). Due to the indefinite composition of the purchased bacitracin standard (Sigma, Deisenhofen, Germany) as well as the instability of bacitracin A against oxidation, the quantification of the major product bacitracin A was carried out based on its antibiotic activity against Micrococcus luteus (see Experimental Procedures). For the constructed B. subtilis strain KE360, a bacitracin A production in 2xYT-media of 8400 IU/l was observed (see Tab. 3). Comparison with the producer strain B. licheniformis ATCC 10716 (5600 IU/l) indicated an increase in bacitracin A production of about 50%.
The composition of the heterologously produced bacitracin-mixture was analyzed using HPLC/MS (see Fig.8 Although members of the genus Bacilli have long been known to produce nonribosomal peptides, B. subtilis has never been used before as a host for recombinant NRPSs production.
This fact likely refers to the described plasmid instability (15, 16) . However, the ability to produce nonribosomal peptides and the well-established genetic and fermentation methods for licheniformis ATCC 10716 (see Tab. 3). Therefore, the ratio of products seems to be determined rather by a strict substrate specificity than by a different substrate availability. On the other hand, the higher level of bacitracin F maybe due to the cellular environment in B.
subtilis that facilitate the oxidation of the peptide product.
So far, the genetic inaccessibility of the native bacitracin producer strain B. licheniformis ATCC 10716 impeded the genetic engineering of the bacitracin biosynthesis gene cluster.
With the construction of the heterologous B. subtilis expression system presented in this study, the engineered manipulation of the corresponding BacABC protein template can be envisioned. The BacABC protein template provides 12 modules with unique activities for 10 different substrate amino acids (see Fig.1 ). Four epimerization domains of different specificity are found as well as a thiazoline ring forming cyclization domain. The thioesterase domain of BacC seems to have an unique specificity to catalyze the formation of only one branched cyclic peptide backbone. The application of genetic strategies for recombination and alteration of individual domains or entire modules have been substantiated by the successful construction of simple model hybrid peptide synthetases in vitro (7, 8) . Now, it is tempering to exploit these strategies to invent a vast set of bacitracin derivatives on demand. Legends to figures subtilis KE355). By screening on Tc-sensitivity, the B. subtilis strain KE360 (C) is obtained. 
